Fig. 2: Increased chromatin accessibility of ARE motifs and NRF2-binding sites in OE19 persister cells.
From: NRF2-mediated persistent adaptation of oesophageal adenocarcinoma cells to HER2 inhibition
A Schematic of experimental design. OE19 cells were treated with lapatinib (500 nM) for 35 days and then lapatinib was withdrawn for 1, 2 or 3 days [17]. PCA plot of ATAC-sequencing performed at the indicated time points (n = 2). The clustering indicates the reproducibly of samples. B Heatmap of differentially accessible ARE-motifs or putative NRF2 binding sites in chromatin after treatment with lapatinib for 35 days and release from therapy relative to mock treated cells with DMSO. NRF2-binding sites were identified from analysing NRF2 ChIP-sequencing datasets from A549 cells [32].
